Fleqsuvy (baclofen) vs Tyruko (natalizumab-sztn)

Fleqsuvy (baclofen) vs Tyruko (natalizumab-sztn)

Fleqsuvy (baclofen) is a muscle relaxer and an antispastic agent primarily used to treat muscle symptoms caused by multiple sclerosis, including spasm, pain, and stiffness, whereas Tyruko (natalizumab-sztn) is a monoclonal antibody designed to interfere with the movement of immune cells into the brain and spinal cord, used to treat relapsing forms of multiple sclerosis and to prevent flare-ups. Baclofen is generally taken orally and works by acting on the central nervous system to produce its muscle relaxant effects, while Tyruko is administered intravenously and targets the immune system to reduce inflammation and damage to the nervous system. The choice between Fleqsuvy and Tyruko would depend on an individual's specific symptoms, the progression of their multiple sclerosis, and their overall treatment plan as determined by a healthcare professional.

Difference between Fleqsuvy and Tyruko

Metric Fleqsuvy (baclofen) Tyruko (natalizumab-sztn)
Generic name Baclofen Natalizumab-sztn
Indications Spasticity management Multiple sclerosis, Crohn's disease
Mechanism of action GABA receptor agonist Integrin inhibitor
Brand names Fleqsuvy Tyruko
Administrative route Oral, intrathecal Intravenous
Side effects Drowsiness, dizziness, weakness Headache, fatigue, urinary tract infections
Contraindications Hypersensitivity to baclofen Progressive multifocal leukoencephalopathy, hypersensitivity to natalizumab
Drug class Muscle relaxant, antispastic agent Monoclonal antibody
Manufacturer Varies by generic manufacturer Biogen

Efficacy

Efficacy of Fleqsuvy (Baclofen) in Multiple Sclerosis (MS)

Fleqsuvy, the brand name for baclofen, is a medication primarily used to treat spasticity, a common symptom in individuals with Multiple Sclerosis (MS). Spasticity refers to the muscle stiffness and involuntary muscle spasms that can be painful and debilitating. The efficacy of baclofen in managing these symptoms is well-documented. It works by acting on the central nervous system to relax muscles, thereby reducing the severity and frequency of muscle spasms. While Fleqsuvy is not a cure for MS, it can significantly improve the quality of life for patients by alleviating some of the discomfort caused by spasticity.

However, the effectiveness of baclofen can vary among individuals, with some experiencing substantial relief and others only a modest improvement. The dosing of baclofen is often tailored to the individual's needs to maximize efficacy while minimizing side effects. It is important to note that while Fleqsuvy can help manage symptoms, it does not slow the progression of MS itself. Patients are advised to work closely with their healthcare providers to determine the optimal dosage and to monitor for any adverse effects.

Efficacy of Tyruko (Natalizumab-sztn) in Multiple Sclerosis (MS)

Tyruko, the brand name for natalizumab-sztn, is a monoclonal antibody used in the treatment of relapsing forms of Multiple Sclerosis (MS). Its efficacy in reducing the frequency of clinical exacerbations and in slowing the progression of physical disability has been established through clinical trials. Natalizumab-sztn works by inhibiting the movement of potentially damaging immune cells from the bloodstream, across the blood-brain barrier, into the brain and spinal cord. This mechanism helps to reduce inflammation and damage to the myelin sheath, the protective covering of nerve fibers that is often attacked in MS.

Clinical studies have shown that Tyruko can lead to a significant reduction in the relapse rate for patients with relapsing-remitting MS (RRMS), and it can also decrease the formation of new lesions in the central nervous system as observed on MRI scans. Despite its efficacy, the use of Tyruko is generally reserved for patients who have not responded adequately to, or cannot tolerate, other treatments for MS due to the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. Patients receiving Tyruko require careful monitoring for signs of PML and other adverse effects.

Regulatory Agency Approvals

Fleqsuvy
  • Food and Drug Administration (FDA), USA
Tyruko
  • European Medical Agency (EMA), European Union
  • Food and Drug Administration (FDA), USA

Access Fleqsuvy or Tyruko today

If Fleqsuvy or Tyruko are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email:

Contact us
LV Latvia 1